| abstract |
Certain highly purified glycosaminoglycan degrading enzymes (chondroitinase B and chondroitinase AC) are used to treat fibroproliferative disorders. The enzymatic removal of chondroitin sulfate B and, to a lesser extent, chondroitin sulfate A or C from the cell surface effectively reduces growth factor receptors on cells, thereby reducing the growth factor In contrast, it reduces the cell proliferative response. Furthermore, the removal of chondroitin sulfate reduces the secretion of collagen, one of the major extracellular matrix components. Fibroblasts found in psoriasis, scleroderma, keloids and surgical adhesions by treatment with chondroitinase B or chondroitinase AC through a combination of inhibition of fibroblast proliferation and collagen synthesis Reduce the size of the. |